MIRA PHARMACEUTICALS, INC.(MIRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MIRA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for MIRA PHARMACEUTICALS, INC. (MIRA), a Healthcare sector company. MIRA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), MIRA PHARMACEUTICALS, INC. reports net income of $-1.2M, free cash flow of $-1.2M. Top institutional holders of MIRA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Cross Staff Investments, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. MIRA trades on the Nasdaq exchange and files with the SEC under CIK 1904286. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MIRA PHARMACEUTICALS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-1.2M
Free Cash Flow
Q1 2026
$-1.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-33.0% YoYEPS (Diluted)
-164.7% YoYTotal Assets
+279.5% YoYOp. Cash Flow
+16.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-10.4M -33.0% | $-7.9M +34.5% | $-12.0M -69.8% | $-7.1M | — |
| EPS (Diluted) | $-1.35 -164.7% | $-0.51 +40.0% | $-0.85 -112.5% | $-0.40 | — |
| Total Assets | $11.1M +279.5% | $2.9M -40.7% | $4.9M +474.8% | $858.1K | — |
| Operating Cash Flow | $-4.7M +16.2% | $-5.6M -22.7% | $-4.5M +19.1% | $-5.6M | — |
AI Insight: MIRA Ratio Trends
Profitability metrics severely underwater across all periods; ROE and ROA showing modest sequential improvement but remain deeply negative.
• ROE improved from -60.3% (Q3 2025) to -49.2% (Q1 2026), a 11.1pp sequential gain; ROA similarly rose from -59.6% to -48.6%.
• TTM ROE stands at -104.9%, indicating sustained unprofitability across the trailing twelve months ending Q1 2026.
⚠ Persistent negative returns across ROE/ROA/ROIC; improvement trend from Q3 2025 to Q1 2026 requires sustained momentum to signal turnaround.
⚠ Most operational metrics (OpMargin, NPM, ROIC, D/E) absent from all periods; limited visibility into underlying operational health.
Get alerted when MIRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MIRA PHARMACEUTICALS, INC. including:
Top Institutional Holders of MIRA
VANGUARD CAPITAL MANAGEMENT LLC
$742.5K693,912 shCross Staff Investments Inc
$384.6K359,401 shGEODE CAPITAL MANAGEMENT, LLC
$311.3K290,890 shVANGUARD FIDUCIARY TRUST CO
$181.3K169,483 shBlackRock, Inc.
$120.2K112,346 shSuncoast Equity Management
$97.0K90,645 shNORTHERN TRUST CORP
$72.4K67,698 shFirst American Bank
$64.2K60,000 shSTATE STREET CORP
$52.5K49,100 shXTX Topco Ltd
$40.2K37,573 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $742.5K | 693,912 |
| Cross Staff Investments Inc | $384.6K | 359,401 |
| GEODE CAPITAL MANAGEMENT, LLC | $311.3K | 290,890 |
| VANGUARD FIDUCIARY TRUST CO | $181.3K | 169,483 |
| BlackRock, Inc. | $120.2K | 112,346 |
| Suncoast Equity Management | $97.0K | 90,645 |
| NORTHERN TRUST CORP | $72.4K | 67,698 |
| First American Bank | $64.2K | 60,000 |
| STATE STREET CORP | $52.5K | 49,100 |
| XTX Topco Ltd | $40.2K | 37,573 |
More Healthcare Companies
View all Healthcare →Put MIRA on your watchlist
Track score changes the day MIRA PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MIRA a good stock to buy?
13F Pro's AI-powered analysis of MIRA PHARMACEUTICALS, INC. (MIRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MIRA are available on the MIRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MIRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MIRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MIRA PHARMACEUTICALS, INC.'s investment landscape.